After 11 years, Sanofi kicks backs the rights to unwanted gene therapies to Oxford Biomedica

Oxford Biomedica is currently most well known for its work on COVID-19 vaccines and its tie-up with AstraZeneca, but a much older deal sits with French Big Pharma Sanofi.

All the way back in 2009, the year of a major viral pandemic , Oxford Biomedica penned a deal to license out its ophthalmology gene therapies, SAR422459 for Stargardt disease, a disease that causes progressive damage of the macula) and SAR421869, for Usher’s Syndrome type 1b where patients are born with severe to profound hearing loss, to Sanofi.